Research centre receives 2 patents
Dr Ramesh Bhat M, research director at the centre, said that a low-cost innovation in simulation-based auscultation training was developed by Dr Reena Wilma Frank, Pradeep D'Souza, Sandra Saldanha, and Dr Lulu Sherif, faculty members of Father Muller Charitable Institutions. The innovators are from nursing, medical, and simulation backgrounds.
Innovation in derma care
In the field of derma care, the 3D-Printed Biodegradable Multipurpose Toe Separator for Dermatological Applications was applied for patent and published by Dr Ramesh Bhat and his team from Fr Muller Medical College and Srinivas University Institute of Engineering and Technology, Mukka.
The team includes Dr Priya Anusha D'Souza, a dermatologist and former student of Fr Muller Medical College, and Ajay Kaushik Noronha, Assistant Professor, Department of MBA at SUIET, Mukka.
The device maintains an open, ventilated interdigital space, which is critical for faster healing and infection prevention. Anatomically tailored for the Indian population, it offers orthopaedic comfort, durability, and ease of use. This invention helps in managing common yet often chronic foot conditions, particularly in humid climates and at-risk groups such as diabetic patients. "So far, we have used this toe separator on 20 patients with good results," he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Gazette
2 hours ago
- India Gazette
Australian's Foreign Minister Penny Wong announces 34 recipients of Maitri Grants
Canberra [Australia], July 13 (ANI): Australia's Minister of Foreign Affairs Penny Wong has announced 34 recipients of this year's Maitri Grants, Fellowships and Scholarships. The Maitri (meaning friendship) Grants, administered by the Centre for Australia-India Relations, aim to support greater exchange and collaboration with India across technology, business, education and culture, according to the statement. The statement said, 'Each project will cultivate deeper connections between our two countries, including: The Lowy Institute's first-ever India Chair, which will lift the quality of research and conversations around India's role as a major power in the Indo-Pacific region. Best-practice playbooks by Asialink Business to support collaboration, capability training and the sharing of successful partnership models in cleantech and agtech.' 'A world-class exhibition featuring rare artworks by renowned Indian painter Raja Ravi Varma at Queensland Art Gallery | Gallery of Modern Art. An incubator of untold narratives from Australia's South Asian diasporas that will showcase Australian-Indian experience to global screen audiences, led by Bodhi Studios,' it added. The 2024-2025 Maitri Grants include 13 Maitri scholarships supporting innovative research across fields like quantum computing technologies and clean energy solutions, and three Maitri fellowships dedicated to exploring opportunities between Australia. The statement said, 'Australia and India's relationship is closer and more important than ever. We are deepening cooperation across priority sectors that are vital to both nations' futures, including in defence, trade, education, and technology.' The recipients of the 2025 Maitri Grants will support connections and research across a wide range of sectors, including innovation, enterprise, education and culture. Administered by the Centre for Australia-India Relations, the Maitri grants encourageinnovative projects and partnerships that reflect the dynamism of the bilateral relationship, fostering long-term connections, according to the Australian High Commission in India press release. Welcoming the announcement, Australia's High Commissioner to India, Philip Green OAM, said, 'Australia's relationship with India is stronger, deeper and more consequential than ever - and its future holds even greater promise. At the heart of this relationship are the people-to-people connections that bind our two nations. The Maitri Grants program builds on these ties, helping unlock the full potential of our bilateral relationship.' 'I congratulate this year's recipients and look forward to seeing how their work helps foster deeper links between Australia and India,' he added. (ANI)
News18
2 hours ago
- News18
‘ISRO Averted Axiom-4 Disaster, Ensured Safety Of Shubhanshu Shukla': V Narayanan Reveals How
Last Updated: ISRO chief V Narayanan said, "On the evening of June 10, we informed SpaceX team to call off the launch. My team was not confident about the rocket's integrity.' Indian Space Research Organisation (ISRO) chief Dr V Narayanan recently revealed that the space agency's decisive stand played a crucial role in the success of Axiom 4, through which Shubhanshu Shukla became the first Indian astronaut to visit the International Space Station (ISS) and the second Indian in orbit after Rakesh Sharma in 1984. The launch, originally scheduled for June 11, was called off on the evening of June 10 after Isro's team detected a leak and later a crack in the Falcon 9 booster. Speaking at the inaugural ceremony of the IEEE International Conference at Presidency University Bengaluru, Narayanan said, he said, 'I was leading the team, and after thorough discussions, we decided not to accept the takeoff. On the evening of June 10, we informed the SpaceX team to call off the launch. My team was not confident about the rocket's integrity and refused to participate." While some dismissed Isro's concerns initially, SpaceX engineers, too, the next day, confirmed the presence of a crack in the Falcon 9 rocket. 'It was a fantastic job of saving the mission," said Narayanan, adding, 'Today, astronaut Shubhanshu Shukla and the entire mission are safe. India is second to none," he said, praising the teamwork that averted potential disaster. Axiom Mission-4 & Shubhanshu Shukla Executed by Axiom Space, in partnership with NASA, ISRO and SpaceX, a four-member crew lifted off aboard a SpaceX Falcon 9 rocket from Launch Complex 39A at NASA's Kennedy Space Center in Florida. The 14-day mission was rescheduled multiple times due to technical issues, including the Falcon 9 leak and problems aboard the ISS. It aimed to conduct major research, including 60 scientific studies and activities representing 31 countries, including the US, India, Poland, Hungary, Saudi Arabia, Brazil, Nigeria, UAE, and nations across Europe. The research will cover space agriculture (e.g. methi, moong daal), tardigrade biology, muscle loss prevention, glucose regulation (Suite Ride diabetes study), cognitive/computer interaction, and more. This will be the most research and science-related activities conducted on an Axiom Space mission aboard the International Space Station to date. These studies include examining muscle regeneration, growth of sprouts and edible microalgae, survival of tiny aquatic organisms, and human interaction with electronic displays in microgravity. The crew will return on July 14. With PTI Inputs view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Economic Times
2 hours ago
- Economic Times
Phase-3 clinical trial enrolment for India's first dengue vaccine to be completed by October: ICMR
Synopsis India's DengiAll vaccine trial is nearing completion. ICMR scientists anticipate enrolling 10,500 participants by October across 20 Indian centers. The phase III trial assesses the Panacea Biotec's one-shot dengue vaccine. Initial trials showed no safety concerns. Participants will be monitored for two years to evaluate efficacy. This is a crucial step as India currently lacks a licensed dengue vaccine. Agencies Representational image Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed dengue vaccine, DengiAll, is likely to be completed by October across 20 centres in India, according to ICMR far, 8,000 participants in various centres at Pune, Chennai, Kolkata, Delhi and Bhubaneswar among others have received either the vaccine or a placebo as part of the trial sponsored by the Indian Council of Medical Research (ICMR) and Panacea Biotec. The trial is co-led by ICMR-National Institute of Translational Virology and AIDS research in Pune, National Institute of Epidemiology (NIE), Chennai and National Institute of Virology, there is no antiviral treatment or licensed vaccine against dengue in results of the Phase-1/2 trial has shown no safety concerns for the one-shot vaccine, NIE Director Dr Manoj Murhekar said. "The participants enrolled in the Phase- III trial will be followed up for two-years. This trial will evaluate the efficacy of this tetravalent dengue vaccine," Dr Murhekar multi-centre, double-blind, randomised, placebo-controlled phase-III trial was launched in August last year to evaluate the jab's efficacy, safety and, long-term immunogenicity. The first participant in this trial was vaccinated at the Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences (PGIMS), Rohtak last year. The development of an effective vaccine is complex due to the need to achieve good efficacy for all four serotypes. The dengue virus has four serotypes, 1-4, with low cross-protection against each other, meaning individuals can experience repeated infections, Dr Murhekar said. In India, all four serotypes of dengue virus are known to circulate or co-circulate in many regions. The Union Health Ministry in a statement earlier had said that the tetravalent dengue vaccine strain (TV003/TV005), originally developed by the National Institutes of Health (NIH), USA, has shown promising results in clinical trials in Brazil. Panacea Biotec, one of three Indian companies to receive the strain, is at the most advanced stage of development. The company has worked extensively on these strains to develop a full-fledged vaccine formulation and holds a process patent for this work. Dengue is a major public health concern in India, ranking among the top 30 countries with the highest incidence of the disease. The global incidence of dengue has been steadily increasing over the past two decades, with more than 129 countries reporting dengue viral disease by the end of 2023, according to the World Health Organisation (WHO).In India, approximately 75-80 per cent of infections are asymptomatic, yet these individuals can still transmit the infection through the bite of Aedes mosquitoes. Among the 20-25 per cent of cases where symptoms are clinically apparent, children are at a significantly higher risk of hospitalisation and mortality. In adults, the disease can escalate into severe conditions like dengue hemorrhagic fever and dengue shock syndrome. According to the government data, around 12,043 dengue cases were reported till March this year. In 2024, 2.3 lakh cases and 297 deaths had been recorded.
